Xilio Therapeutics Inc (XLO)
1.07
0.00 (0.00%)
USD |
NASDAQ |
May 24, 15:38
Xilio Therapeutics Research and Development Expense (Annual): 52.14M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2023 | 52.14M |
| December 31, 2022 | 59.20M |
| December 31, 2021 | 51.19M |
| Date | Value |
|---|---|
| December 31, 2020 | 43.91M |
| December 31, 2019 | 14.26M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
14.26M
Minimum
2019
59.20M
Maximum
2022
44.14M
Average
51.19M
Median
2021
Research and Development Expense (Annual) Benchmarks
| Gilead Sciences Inc | 5.718B |
| FibroGen Inc | 282.86M |
| Avalo Therapeutics Inc | 13.78M |
| IGM Biosciences Inc | 215.52M |
| AEON Biopharma Inc | 34.75M |